New Study Release: How Limiting Cost Sharing for Specialty Drugs Would Impact Insurance Premiums
Tuesday, September 10, 2013 • 2:00 pm
2456 Rayburn House Office Building
Please join the Coalition for Accessible Treatments for the release of a new study by Avalere Health, LLC estimating the impact of the H.R. 460 on premiums and cost sharing in commercial health plans.
Featured speakers include: Representatives David McKinley (R-WV) and Lois Capps (D-CA), co-sponsors of H.R. 460, the Patients’ Access to Treatments Act of 2013, along with patients who struggle to pay for their vital, life-saving treatments. Study findings presented by Avalere Health, LLC.
Millions of Americans live with chronic, disabling, life-threatening diseases such as rheumatoid arthritis, lupus, psoriasis, and certain cancers. Many of these chronic conditions require specialty treatments that cost thousands of dollars and years to develop. Because of costs, health insurance companies place these vital, life-changing and life-saving medications on a specialty tier and charge a co-insurance or percentage of the cost placing a substantial financial burden on these patients.
This is a widely attended event.
RSVP to Geoff Steber at email@example.com or (202) 887-2920
The briefing is sponsored by the Coalition for Accessible Treatments: American Academy of Dermatology Association, American Academy of Neurology, American Academy of Pediatrics, American Autoimmune Related Diseases Association, American College of Rheumatology, American Plasma Users Coalition, Arthritis Foundation, the Crohn’s & Colitis Foundation of America, Colon Cancer Alliance, GBS/CIDP Foundation International, Hemophilia Federation of America, Immune Deficiency Foundation, Leukemia & Lymphoma Society, Lupus Foundation of America, National Hemophilia Foundation, National Organization for Rare Disorders, National Psoriasis Foundation, Patient Services Incorporated, Pulmonary Hypertension Association, Sjögren’s Syndrome Foundation, Spondylitis Association of America, The Alliance for Patient Advocacy, and the US Hereditary Angioedema Association.